Shattuck Labs, Inc.
NASDAQ:STTKBiotechnology
+$0.11 today
- Market cap
- $463.38M
- Beta
- 1.09
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$0.44
Volume 1.39M
Average 0.69M
STTK Account Payables
Amounts the company owes suppliers for goods and services received.
Shattuck Labs, Inc.NASDAQ: STTK
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 18.3% from a year ago
Account payables stood at $1.25M at the end of Q1 FY2026, down 18.3% from a year earlier and down 40.4% from the prior quarter. Over 3 fiscal years it compounded at -33.6% a year.
Context
- Account payables amounted to 1.2% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -18.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.1M USD
- Year-over-year change
- -13.1%
- 4-year CAGR
- -32.3%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.1M | -13.1% |
| FY2024 | 2024-12-31 | 2.42M | +52.4% |
| FY2023 | 2023-12-31 | 1.59M | -77.9% |
| FY2022 | 2022-12-31 | 7.17M | -28.4% |
| FY2021 | 2021-12-31 | 10.01M | — |
Account Payables vs competitors
How STTK compares with its peers on the latest reported figures
- STTK's Mar 2026 account payables of $1.25M is the 7th highest of the 10 companies compared; the peer median is $2.15M.
- Its year-over-year change of -18.3% is the 7th highest of 9, against a peer median of +20.3%.
- Account payables amounts to 1.2% of total assets for STTK, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $21.65M | -30.7% | -5.9% | 2.2% | |
| Mar 2026 | $8.17M | +35.5% | -7.7% | 4.2% | |
| Mar 2026 | $3.65M | +27.7% | +43.1% | 14.8% | |
| Mar 2026 | $2.97M | +13.0% | -32.4% | 2.2% | |
| Jun 2026 | $2.15M | +511.7% | -46.4% | 1.1% | |
| Sep 2026 | $2.09M | -9.4% | -4.2% | 1.5% | |
| Mar 2026 | $1.25M | -18.3% | -33.6% | 1.2% | |
| Mar 2026 | $1.19M | +702.7% | +117.6% | 0.6% | |
| Mar 2026 | $557.37K | -57.5% | -26.6% | 25.6% | |
NBPNovaBridge Biosciences | Dec 2025 | $0 | — | — | 0.0% |
| Peer median (excluding STTK) | $2.15M | +20.3% | -6.8% | 2.2% | |
Competitors are the stored peer set for STTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 92.27M | 47.38M | 125.63M | 57.39M | 54.19M |
| Short-term Investments | 176.54M | 113.9M | 5M | 15.6M | 23.87M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 23.3M | 12.6M | 6.23M | 4.41M |
| Total Current Assets | 288.27M | 184.58M | 143.22M | 79.22M | 82.48M |
| Property, Plant & Equipment (Net) | 9.94M | 17.67M | 13.8M | 9.81M | 6.11M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 1M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 381K | 3.07M | 2.54M | 2.02M | 1.44M |
| Total Non-current Assets | 10.32M | 20.74M | 16.34M | 11.83M | 8.55M |
| Total Assets | 298.59M | 205.32M | 159.56M | 91.05M | 91.03M |
| Account Payables | 10.01M | 7.17M | 1.59M | 2.42M | 2.1M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.25M | 5.84M | 4.84M | 2.7M | 3M |
| Total Current Liabilities | 24.59M | 24.97M | 11.45M | 8.92M | 7.05M |
| Long-term Debt | 0 | 0 | 0 | 0 | 1.58M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.21M | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 2.21M | 4.2M | 3.41M | 2.51M | 1.58M |
| Total Liabilities | 26.8M | 29.17M | 14.86M | 11.42M | 8.64M |
| Common Stock | 5K | 5K | 5K | 5K | 7K |
| Retained Earnings | (117.07M) | (219.01M) | (306.31M) | (381.72M) | (430.53M) |
| Accumulated OCI | (560K) | (877K) | 4K | 2K | 6K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 271.79M | 176.16M | 144.71M | 79.63M | 82.39M |
| Total Debt | 0 | 4.9M | 4.2M | 3.41M | 2.42M |
| Net Debt | (92.27M) | (42.48M) | (121.42M) | (53.98M) | (51.77M) |
Shattuck Labs, Inc.
NASDAQ:STTK
Intrinsic Alpha fair value
Locked
Current Price
$4.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.